Eye specialist service provider, Optimax has obtained a licence from the Ministry of Health Malaysia to offer plastic surgery and aesthetic services. We will discuss this decision to pivot to other services, their latest financial results, and share price performance with 2nd generation leader Sandy Tan, the CEO of Optimax Holdings. And whether this new vision of aesthetic services will help turn around their share price which has dropped 13% year to date.

Can ASEAN’s Digital Needs Push EdgePoint Past Key Pressures?
23:32

Pharmaniaga Post-PN17 Betting Big on Biopharma
23:56

Khairy Jamaluddin: Back in the Running
34:25